Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.40 USD

74.40
785,910

+0.62 (0.84%)

Updated Aug 19, 2024 11:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $70.86, marking a -1.5% move from the previous day.

Shire's Takhzyro Gets European Nod for Hereditary Angioedema

by Zacks Equity Research

Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate

by Zacks Equity Research

The FDA's BRUDAC committee will review Amgen (AMGN) and its European partner UCB's BLA for Evenity so that the candidate gets approved for treating osteoporosis in postmenopausal women.

Indrajit Bandyopadhyay headshot

Key Pharma Players With HIV Focus Ahead of World Aids Day

by Indrajit Bandyopadhyay

We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.

Bayer (BAYRY) to Restructure Business & Reduce Headcount

by Zacks Equity Research

Bayer (BAYRY) conducts a strategic review of its business model, and plans to exit unprofitable product lines and reduce headcount.

Merck (MRK) Receives Approval for 2 HIV Medicines in EU

by Zacks Equity Research

Merck's (MRK) two new HIV drugs, Pifeltro and Delstrigo, containing doravirine, get approval in EU.

Roche (RHHBY) to Acquire Jecure and Enter the NASH Space

by Zacks Equity Research

Roche (RHHBY) is all set to acquire biotech Jecure Therapeutics, which focuses on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis.

Catalyst's Firdapse Receives FDA Approval for Rare Disease

by Zacks Equity Research

Catalyst's (CPRX) Firdapse gets FDA approval for the treatment of LEMS in adults.

Novartis (NVS) Receives EC Approval for Neulasta Biosimilar

by Zacks Equity Research

Novartis (NVS) obtains EC approval for Ziextenzo, the biosimilar of Amgen's Neulasta.

Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity

by Zacks Equity Research

Pfizer (PFE) receives pediatric exclusivity for its epilepsy drug, Lyrica, extending the exclusivity period to Jun 30, 2019.

Celgene & Bluebird's CAR T Therapy Study Completes Enrollment

by Zacks Equity Research

Celgene (CELG) and partner bluebird complete enrollment in a phase II study for CAR T cell therapy candidate, bb2121 for patients with relapsed and refractory multiple myeloma.

Aileron Inks Collaboration Deal With Pfizer for Cancer Combo

by Zacks Equity Research

Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.

Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial

by Zacks Equity Research

Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.

Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate

by Zacks Equity Research

Alnylam (ALNY) and Vir commence phase I/II study for VIR-2218 for the treatment of chronic HBV infection.

Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial

by Zacks Equity Research

Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with Yervoy fails to meet the goal in a late-stage study for extensive-stage SCLC.

Eyenovia Initiates Phase III Study for Mydriasis Candidate

by Zacks Equity Research

Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.

Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors

by Zacks Equity Research

Bayer (BAYRY) receives the FDA approval for larotrectinib for the treatment of adult and pediatric patients having solid tumors with NTRK gene fusion.

Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth

by Zacks Equity Research

Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.

Novartis Gets Approval for Gene Therapy Luxturna in Europe

by Zacks Equity Research

Novartis (NVS) obtains EC approval for a one-time gene therapy, Luxturna for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65gene.

Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal

by Zacks Equity Research

Regulatory news and licensing contracts are key highlights in the biotech sector this week.

Should Value Investors Consider Gilead (GILD) Stock Now?

by Zacks Equity Research

Let's see if Gilead Sciences, Inc. (GILD) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Gilead's Vemlidy Gets Approval in China for HBV Infection

by Zacks Equity Research

Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.

Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint

by Zacks Equity Research

Emergent BioSolutions (EBS) and partner Valneva present positive data from an early-stage study on the Zika vaccine candidate, VLA1601.

Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta

by Zacks Equity Research

Novartis (NVS) obtains FDA approval for the label expansion of Promacta. The CHMP also issues a positive opinion for the label expansion of Kisqali.

Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension

by Zacks Equity Research

Amgen's (AMGN) leukemia drug, Blincyto receives positive CHMP opinion for label expansion to include minimal residual disease.